Exchange: NASDAQ·Updated 08:08 AM EDT
MGNX logo

MGNX Macrogenics Inc

$4.17
$0.00
(0.00%)
Pre-Market
Prev Close $4.17
Reported EarningsAug 13
Mkt Cap$265.63M
Vol52.00

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
40

Bearish Sentiment

How do you feel about MGNX?

Advertisement|Remove ads.